Allied Market Research published a report, titled, "Cytogenetics Market by Product (Consumable, Instrument, Software and Service), by Technique (Comparative Genome Hybridization, Fluorescence in Situ ...
Molecular Instruments® (MI), founded by the inventor of the HCRâ„¢ technology, today announces the launch of the HCRâ„¢ Gold and ...
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer ...
The technology, FISH-scRACS-seq (Fluorescence In Situ Hybridization-guided Single-Cell Raman-activated Sorting and Sequencing), utilizes a Raman-activated optical tweezers-based cell sorter ...
All positive (IHC 3+) and doubtful (IHC 2+) cases were screened by fl uorescence in situ hybridization (FISH). Patients with HER2 gene amplification, normal left ventricular ejection fraction ...
The researchers also noted that patients with IHC 2+ and in situ hybridization-amplified disease derived less benefit from T-DM1 compared to the IHC 3+ population, suggesting a need for more ...